FDA Drug Safety Communication (2015) FDA Revises Labels of SGLT2 Inhibitors for Diabetes to Include Warnings about Too Much Acid in the Blood and Serious Urinary Tract Infections. Posted 12 April 2015.

has been cited by the following article:

• TITLE: Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True!

  AUTHORS: Udaya M. Kabadi

  KEYWORDS: Review Paper

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.6 No.2, April 20, 2016

  ABSTRACT: It was interesting to read the recent article regarding the efficacy of Empagliflozin in reducing all cause and cardiovascular mortality [1]. Superficially, the report appears to be very promising. However, the methodology, the results and the conclusions deserve and need further scrutiny and validation for several reasons.